KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Gains from Investment Securities (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Gains from Investment Securities for 7 consecutive years, with $1.8 million as the latest value for Q2 2024.

  • For the quarter ending Q2 2024, Gains from Investment Securities changed N/A year-over-year to $1.8 million, compared with a TTM value of $917000.0 through Sep 2015, down 89.01%, and an annual FY2018 reading of $4.5 million, up 129.33% over the prior year.
  • Gains from Investment Securities was $1.8 million for Q2 2024 at Biocryst Pharmaceuticals, down from $2.4 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $2.4 million in Q1 2024 and bottomed at $1.8 million in Q2 2024.